Tags

Type your tag names separated by a space and hit enter

Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.
Clin Neuropharmacol. 2017 Jul/Aug; 40(4):169-174.CN

Abstract

Calcitonin gene-related peptide (CGRP) is a signaling neuropeptide released from activated trigeminal sensory afferents in headache and facial pain disorders. There are a handful of CGRP-targeted therapies currently in phase 3 studies for migraine acute treatment or prevention. Currently, 4 monoclonal antibodies targeting either the CGRP ligand or receptor are being studied for migraine prevention: ALD403 (eptinezumab), AMG 334 (erenumab), LY2951742 (galcanezumab), and TEV-48125 (fremanezumab). Meanwhile, 1 small-molecule CGRP receptor antagonist (ubrogepant, MK-1602) is currently in phase 3 studies for the acute treatment of migraine. Two of these anti-CGRP monoclonal antibodies are in clinical trials for cluster headache prevention as well. Several other small-molecular CGRP receptor antagonists are in earlier stages of development for acute migraine treatment or prevention. In this review, we will discuss the growing body of clinical trials studying CGRP-targeted therapies for migraine and cluster headache.

Authors+Show Affiliations

*Center for Pain Medicine, Department of Anesthesia, Critical Care, and Pain Medicine, Wang Ambulatory Care Center, Boston, MA; and †Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28644160

Citation

Schuster, Nathaniel M., and Alan M. Rapoport. "Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: a Review." Clinical Neuropharmacology, vol. 40, no. 4, 2017, pp. 169-174.
Schuster NM, Rapoport AM. Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review. Clin Neuropharmacol. 2017;40(4):169-174.
Schuster, N. M., & Rapoport, A. M. (2017). Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review. Clinical Neuropharmacology, 40(4), 169-174. https://doi.org/10.1097/WNF.0000000000000227
Schuster NM, Rapoport AM. Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: a Review. Clin Neuropharmacol. 2017 Jul/Aug;40(4):169-174. PubMed PMID: 28644160.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review. AU - Schuster,Nathaniel M, AU - Rapoport,Alan M, PY - 2017/6/24/pubmed PY - 2018/4/12/medline PY - 2017/6/24/entrez SP - 169 EP - 174 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 40 IS - 4 N2 - Calcitonin gene-related peptide (CGRP) is a signaling neuropeptide released from activated trigeminal sensory afferents in headache and facial pain disorders. There are a handful of CGRP-targeted therapies currently in phase 3 studies for migraine acute treatment or prevention. Currently, 4 monoclonal antibodies targeting either the CGRP ligand or receptor are being studied for migraine prevention: ALD403 (eptinezumab), AMG 334 (erenumab), LY2951742 (galcanezumab), and TEV-48125 (fremanezumab). Meanwhile, 1 small-molecule CGRP receptor antagonist (ubrogepant, MK-1602) is currently in phase 3 studies for the acute treatment of migraine. Two of these anti-CGRP monoclonal antibodies are in clinical trials for cluster headache prevention as well. Several other small-molecular CGRP receptor antagonists are in earlier stages of development for acute migraine treatment or prevention. In this review, we will discuss the growing body of clinical trials studying CGRP-targeted therapies for migraine and cluster headache. SN - 1537-162X UR - https://www.unboundmedicine.com/medline/citation/28644160/Calcitonin_Gene_Related_Peptide_Targeted_Therapies_for_Migraine_and_Cluster_Headache:_A_Review_ L2 - https://doi.org/10.1097/WNF.0000000000000227 DB - PRIME DP - Unbound Medicine ER -